Baiya SARS CoV 2 Vax 1
Alternative Names: Baiya-SARS-CoV-2-Vax-1; RBD-Fc-based Vaccine; Recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccineLatest Information Update: 27 Jan 2023
At a glance
- Originator Baiya Phytopharm
- Class COVID-19 vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 04 Nov 2022 Baiya Phytopharm completes phase I trial in COVID-2019 infections (Prevention) in Thailand (IM) (NCT04953078)
- 11 Sep 2021 Phase-I clinical trials in COVID-2019 infections (Prevention) in Thailand (IM) (NCT04953078)
- 07 Jul 2021 Baiya Phytopharm in collaboration with National Vaccine Institute plans a phase I trial in COVID-2019 infections (Prevention) (IM, Injection) in September 2021 (NCT04953078)